tadhana slot online game
Minority couple sells new house after protests from housing society in MoradabadTHOUSAND OAKS, Calif. , Dec. 2, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at Citi's 2024 Global Healthcare Conference at 9:30 a.m. ET on Thursday , Dec. 5, 2024. Peter Griffith , executive vice president and chief financial officer at Amgen, Jay Bradner , executive vice president of Research and Development and chief scientific officer at Amgen, and Susan Sweeney , executive vice president of Obesity and Related Conditions at Amgen, will participate in a fireside chat at the conference. The webcast will be broadcast over the internet simultaneously and will be available to members of the news media, investors and the general public. The webcast, as with other selected presentations regarding developments in Amgen's business given by management at certain investor and medical conferences, can be found on Amgen's website, www.amgen.com , under Investors. Information regarding presentation times, webcast availability and webcast links are noted on Amgen's Investor Relations Events Calendar. The webcast will be archived and available for replay for at least 90 days after the event. About Amgen Amgen discovers, develops, manufactures and delivers innovative medicines to help millions of patients in their fight against some of the world's toughest diseases. More than 40 years ago, Amgen helped to establish the biotechnology industry and remains on the cutting-edge of innovation, using technology and human genetic data to push beyond what's known today. Amgen is advancing a broad and deep pipeline that builds on its existing portfolio of medicines to treat cancer, heart disease, osteoporosis, inflammatory diseases and rare diseases. In 2024, Amgen was named one of the "World's Most Innovative Companies" by Fast Company and one of "America's Best Large Employers" by Forbes, among other external recognitions . Amgen is one of the 30 companies that comprise the Dow Jones Industrial Average ® , and it is also part of the Nasdaq-100 Index ® , which includes the largest and most innovative non-financial companies listed on the Nasdaq Stock Market based on market capitalization. Amgen is one of the 30 companies that comprise the Dow Jones Industrial Average and is also part of the Nasdaq-100 index. In 2023, Amgen was named one of "America's Greatest Workplaces" by Newsweek, one of "America's Climate Leaders" by USA Today and one of the "World's Best Companies" by TIME. For more information, visit Amgen.com and follow us on X (formerly known as Twitter), LinkedIn , Instagram , TikTok , YouTube and Threads . Amgen Forward-Looking Statements This news release contains forward-looking statements that are based on the current expectations and beliefs of Amgen. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including any statements on the outcome, benefits and synergies of collaborations, or potential collaborations, with any other company (including BeiGene, Ltd. or Kyowa Kirin Co., Ltd.), the performance of Otezla ® (apremilast) (including anticipated Otezla sales growth and the timing of non-GAAP EPS accretion), our acquisitions of Teneobio, Inc., ChemoCentryx, Inc., or Horizon Therapeutics plc (including the prospective performance and outlook of Horizon's business, performance and opportunities, any potential strategic benefits, synergies or opportunities expected as a result of such acquisition, and any projected impacts from the Horizon acquisition on our acquisition-related expenses going forward), as well as estimates of revenues, operating margins, capital expenditures, cash, other financial metrics, expected legal, arbitration, political, regulatory or clinical results or practices, customer and prescriber patterns or practices, reimbursement activities and outcomes, effects of pandemics or other widespread health problems on our business, outcomes, progress, and other such estimates and results. Forward-looking statements involve significant risks and uncertainties, including those discussed below and more fully described in the Securities and Exchange Commission reports filed by Amgen, including our most recent annual report on Form 10-K and any subsequent periodic reports on Form 10-Q and current reports on Form 8-K. Unless otherwise noted, Amgen is providing this information as of the date of this news release and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise. No forward-looking statement can be guaranteed and actual results may differ materially from those we project. Our results may be affected by our ability to successfully market both new and existing products domestically and internationally, clinical and regulatory developments involving current and future products, sales growth of recently launched products, competition from other products including biosimilars, difficulties or delays in manufacturing our products and global economic conditions. In addition, sales of our products are affected by pricing pressure, political and public scrutiny and reimbursement policies imposed by third-party payers, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment. Furthermore, our research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. We or others could identify safety, side effects or manufacturing problems with our products, including our devices, after they are on the market. Our business may be impacted by government investigations, litigation and product liability claims. In addition, our business may be impacted by the adoption of new tax legislation or exposure to additional tax liabilities. If we fail to meet the compliance obligations in the corporate integrity agreement between us and the U.S. government, we could become subject to significant sanctions. Further, while we routinely obtain patents for our products and technology, the protection offered by our patents and patent applications may be challenged, invalidated or circumvented by our competitors, or we may fail to prevail in present and future intellectual property litigation. We perform a substantial amount of our commercial manufacturing activities at a few key facilities, including in Puerto Rico , and also depend on third parties for a portion of our manufacturing activities, and limits on supply may constrain sales of certain of our current products and product candidate development. An outbreak of disease or similar public health threat, such as COVID-19, and the public and governmental effort to mitigate against the spread of such disease, could have a significant adverse effect on the supply of materials for our manufacturing activities, the distribution of our products, the commercialization of our product candidates, and our clinical trial operations, and any such events may have a material adverse effect on our product development, product sales, business and results of operations. We rely on collaborations with third parties for the development of some of our product candidates and for the commercialization and sales of some of our commercial products. In addition, we compete with other companies with respect to many of our marketed products as well as for the discovery and development of new products. Discovery or identification of new product candidates or development of new indications for existing products cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate or development of a new indication for an existing product will be successful and become a commercial product. Further, some raw materials, medical devices and component parts for our products are supplied by sole third-party suppliers. Certain of our distributors, customers and payers have substantial purchasing leverage in their dealings with us. The discovery of significant problems with a product similar to one of our products that implicate an entire class of products could have a material adverse effect on sales of the affected products and on our business and results of operations. Our efforts to collaborate with or acquire other companies, products or technology, and to integrate the operations of companies or to support the products or technology we have acquired, may not be successful. There can be no guarantee that we will be able to realize any of the strategic benefits, synergies or opportunities arising from the Horizon acquisition, and such benefits, synergies or opportunities may take longer to realize than expected. We may not be able to successfully integrate Horizon, and such integration may take longer, be more difficult or cost more than expected. A breakdown, cyberattack or information security breach of our information technology systems could compromise the confidentiality, integrity and availability of our systems and our data. Our stock price is volatile and may be affected by a number of events. Our business and operations may be negatively affected by the failure, or perceived failure, of achieving our environmental, social and governance objectives. The effects of global climate change and related natural disasters could negatively affect our business and operations. Global economic conditions may magnify certain risks that affect our business. Our business performance could affect or limit the ability of our Board of Directors to declare a dividend or our ability to pay a dividend or repurchase our common stock. We may not be able to access the capital and credit markets on terms that are favorable to us, or at all. CONTACT: Amgen, Thousand Oaks Elissa Snook , 609-251-1407 (media) Justin Claeys , 805-313-9775 (investors) View original content to download multimedia: https://www.prnewswire.com/news-releases/amgen-to-present-at-citis-2024-global-healthcare-conference-302319891.html SOURCE Amgen
Gary Yeowell What I have learned is that, often, successful investing means going against popular opinion. This is not always true, but it is true more often than it isn't. A good example of this can be seen by looking at my rating history when it comes Crude Value Insights offers you an investing service and community focused on oil and natural gas. We focus on cash flow and the companies that generate it, leading to value and growth prospects with real potential. Subscribers get to use a 50+ stock model account, in-depth cash flow analyses of E&P firms, and live chat discussion of the sector. Sign up today for your two-week free trial and get a new lease on oil & gas! Daniel is an avid and active professional investor. Crude Value Insights Learn more Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.KUWAIT: His Highness Sheikh Sabah Al-Khaled Al-Hamad Al-Sabah has had an eventful debut year as Crown Prince, with a series of diplomatic, social, and international engagements that highlight Kuwait’s active role in regional and global affairs. From hosting official visits to addressing international forums, His Highness has been at the forefront of key national and international events throughout 2024. National unity and diplomacy On June 1, 2024, Sheikh Sabah Al-Khaled was appointed Crown Prince of Kuwait, taking the oath of office the following day, June 2. His Highness began his tenure with a series of important meetings, starting with a gathering on June 10 with members of the Al-Sabah family at the family Diwan in Bayan Palace. The meeting underscored the importance of unity and solidarity within the leadership of Kuwait. Later that month, His Highness the Crown Prince hosted a gathering at Bayan Palace, welcoming a large number of citizens and further solidifying his commitment to maintaining open communication with the public. Global engagement A few days after taking the oath as Crown Prince, His Highness held pivotal talks with Prince Mohammed bin Salman, Crown Prince and Prime Minister of Saudi Arabia, during an official visit to the Kingdom. The meeting took place at the Peace Palace in Jeddah, focusing on strengthening bilateral ties between Kuwait and Saudi Arabia. As part of his international engagements, His Highness the Crown Prince traveled to New York in September to head Kuwait’s delegation at the 79th session of the United Nations General Assembly. During his visit, he delivered Kuwait’s speech at the Future Summit and participated in the General Debate, where he addressed global issues and Kuwait’s role in promoting peace and cooperation on the international stage. His Highness’s activities also included the celebration of the anniversary of the Istanbul Cooperation Initiative on September 26, where he underscored Kuwait’s dedication to regional cooperation and multilateral collaboration. On October 2, His Highness arrived in Doha to lead the Kuwaiti delegation at the 3rd Asia Cooperation Dialogue Summit. His participation in this summit aimed to enhance Kuwait’s role in fostering closer ties within the Asian region, promoting dialogue and cooperation on key economic and political issues. Global security and climate action In November, His Highness the Crown Prince delivered the opening speech at the 4th International Conference on “Enhancing International Cooperation in Combating Terrorism,” held in Kuwait. The conference, which was attended by over 450 participants from United Nations member states, aimed to strengthen international cooperation in combating terrorism and promoting peace and security. Additionally, His Highness the Crown Prince played a key role at the extraordinary Arab-Islamic Summit in Riyadh on November 11, where he addressed regional issues and the importance of unity among Arab and Islamic nations in addressing common challenges. In a significant contribution to global climate efforts, His Highness also participated in the 29th Conference of the Parties to the United Nations Framework Convention on Climate Change (COP29) in Baku, Azerbaijan, on November 13. In his address, he emphasized Kuwait’s commitment to tackling climate change and fostering international cooperation to achieve sustainable development. Strengthening regional ties The year ended with a significant visit from Prince Hussein bin Abdullah II, Crown Prince of Jordan, who visited Kuwait on December 15. His Highness the Crown Prince Sheikh Sabah Khaled Al-Hamad Al-Sabah warmly received Prince Hussein at Bayan Palace, marking a strong reaffirmation of the ties between Kuwait and Jordan. Throughout 2024, His Highness the Crown Prince has shown exemplary leadership in reinforcing Kuwait’s diplomatic relations, both regionally and globally. His engagements have highlighted his dedication to strengthening Kuwait’s position on the world stage, addressing critical issues such as international security, climate change, and sustainable development, while continuing to foster unity and cooperation at home. The Crown Prince’s active participation in these high-level meetings, summits, and official visits further underscores his commitment to advancing Kuwait’s foreign policy objectives and promoting the country’s interests in various international forums.
AP Trending SummaryBrief at 5:52 p.m. ESTAs the Nottingham Forest supporters filed out of Goodison Park they roared in unison: “We’re going to win the league.” The chances are they will not, but the sound of their celebrations at the end of this match were almost as galling to some Everton supporters as the prospect of Liverpool, the only team above them after this win, being the ones to stop them. Their joy, and the fun that away end is having up and down the country, is a feeling that has long been alien to Blues through several seasons of misery. There have been bursts of spirit - the week of three wins, including in the Merseyside derby, among them. And there are plenty of reasons for Everton supporters to look forward to the future as the club stabilises under new owners ahead of the summer move to a new home that should be transformative to its ambitions. Sean Dyche knows who will get the blame for dismal Everton defeat to Nottingham Forest Everton player ratings as two terrible in dismal Nottingham Forest loss This is the present though and the final year at Goodison was marred by another away win on a dreary Sunday afternoon in which Everton struggled to compete with a side that was in disarray when it became the first of those three sides slain during the heady days of April. Back then, Forest looked more chaotic than Everton. Having become the second side to suffer the ignominy of a Premier League points deduction their defeat in L4 forced them deeper into the relegation fight it saved Everton from. The result was so significant it shredded the visitors’ nerves, fuelling a frantic outburst on social media that had disciplinary repercussions. But Forest eventually pulled clear of the trouble and this season they are having a campaign they could only have dreamt of in August. That is the problem for Sean Dyche and for those who make the decisions at Everton. Forest are the latest side to show that a team can go from a relegation fight to one that inspires hope and draws supporters into thinking that any match could yield three points. Everton have not done that. The league is littered with examples of clubs that have grown on and off the pitch into teams that provide belief to their supporters. In contrast, Everton remain trapped in that cycle of struggle. This is a club that has not been as well-run as the likes of Brighton and Hove Albion or Brentford, and have had less money to spend than Forest - it will have been lost on few that the best player on the pitch, Morgan Gibbs-White, was one of several missed targets of recent summers. So too was Anthony Elanga, another thorn in Everton’s side. Supporters know that. But they are not wrong to want more than a side that, at its best, can stubbornly fight for draws against those with Champions League ambitions but then struggles to muster a threat when they face a lesser light. As tough as it might be, this fanbase is justified in its hope the final campaign at the Grand Old Lady would not be one of forlorn journeys home after listening to away end after away end enjoy their final trip to Goodison. The pressure to improve is one that will be passed on to new owners The Friedkin Group very quickly. The stability, resources and expertise they will bring should make progress possible. Whatever Dyche’s long-term role under them turns out to be, it should not be forgotten what he has achieved while labouring under the chastening constraints of the old regime, and that he is yet to see the tangible benefit of change. He remains locked in a struggle with results and expectation though. For all the positivity inspired by the draws against Arsenal, Chelsea and Manchester City, Everton have won just three times in 18 games this season and with Crystal Palace and Wolverhampton Wanderers now improving, they lie just three points ahead of third bottom Leicester City. Until draws turn into wins the fear that Ruud van Nistelrooy’s side are just an unexpected win from catching them will linger and fester. That is the second reason why games like this hurt to those whose dreams are attached to the fortunes of Everton. While Forest are showing that a change in fortunes is possible with the right level of organisation and ambition, on Sunday they showed what can be achieved with fight and maturity on the pitch. Everton’s small squad may well have been tired after three brave draws but they failed to lay a glove on a Forest side that, while in form, should not have been given the freedom to enact their gameplan so effectively. They were timid, slow and once again unimaginative going forward. That failure is on the players and the manager and must be addressed immediately with further tricky games ahead. The truth of this match is that Forest kept Everton at a distance. Through goalscorers Chris Wood and Gibbs-White they were stronger and more intelligent than an Everton side that appeared bereft of ideas. As Dyche attempted to break through the attacking struggles of the season so far by dropping Dominic Calvert-Lewin for Armando Broja, this was a reminder that different personnel can only change so much if the approach is not altered. How enviously Broja and Calvert-Lewin must have watched Wood in action. Forest do not approach games too differently to Everton - they do not like possession, they look to counter, they like a physical figure up top. But the big difference between the teams is the support offered to Wood. For so much of this season Calvert-Lewin has been isolated, even more so since Dyche decided - with some success - to sacrifice attacking ambition to improve defensively by moving Abdoulaye Doucoure to the number 10. That change had yielded six points and three clean sheets through four unbeaten matches but it is one that has its limitations, as was clear against Forest, and does not solve the problems still facing a side that needs more wins. Because of the continued struggle up top, once the away team took the lead, this game looked lost for Everton. And it was a goal that showcased the difference in approach, the difference in ambition. When Wood won Gibbs-White’s long ball forward he had Anthony Elanga close enough to him to claim the second ball. His flick found Wood, whose lofted finish was cute and took his personal tally to within three of Everton’s total number of league goals for the campaign. The goal had looked increasingly likely when it came midway through the first half. Wood had already volleyed over after linking up well with Elliot Anderson, another player who offered him support, and headed just wide from a well-placed Elanga cross. As Everton sought a response Broja fought hard but was often operating alone and was forced to feed on scraps and manufacture chances for himself. The excellent Gibbs-White created the best chance of the half when he played Elanga through on goal only for the winger to shoot wide on half-time. In the second half Everton continued to labour but it was again Forest that presented the bigger threat. They were happy for Everton to take the ball and comfortable at dealing with what the hosts threw at them. They also played with greater composure. While Forest were dangerous on the break it was Everton who created the goal that sealed this away win, Doucoure’s pass dropping short of James Tarkowski and Vitali Mykolenko, allowing Elanga to steal in. He combined with Wood to send Gibbs-White into the box to finish this as a contest. Dyche rang the changes but to little effect. It was not until the 80th minute that Everton had their first shot on target as Calvert-Lewin, one of the substitutes, headed tamely at Matz Sels. Another second half arrival, Beto, forced Sels into a tougher stop but, save for the persistence of Iliman Ndiaye, Forest were given little to worry about. At the end, they still looked more likely to score and should have made it three when an Everton corner became a counter attack that saw Elanga miss a second one-on-one with Pickford, who then saved from Taiwo Awoniyi’s effort off the rebound. The misses, of course, did little to quieten that celebrating away end. Everton and Dyche have problems to solve and this match was a reminder of the fight they are still in. The Blues boss has overseen an upturn in results in what has been a very good December on and off the pitch for the club. The emotion of wanting to finish well at Goodison should not detract from the realities of the challenges still facing this club. But the promise of better days will still feel distant unless and until Everton begin to pick up wins.
Arizona Behavioral Health Hospitals Struggle Financially Amid Overall Hospital Profitability Gains
The No. 2 Nebraska Cornhuskers will face the No. 6 Wisconsin Badgers on Saturday, November 23 as they fight for the regular season title. The game is scheduled to start at 8 p.m. ET on The Big Ten Network. Fans looking to watch this women’s college volleyball game can do so for free by using FuboTV , which offers a free trial and $20 off your first month, or DirecTV Stream , which also offers a free trial. SlingTV doesn’t offer a free trial but does have other promotional offers available. In their last meeting, No. 2 Nebraska swept No. 6 Wisconsin at the UW Field House, snapping an eight-match skid in Madison. The Huskers' defense held Wisconsin to a .094 hitting percentage, their lowest since 2016. The Huskers remain unbeaten in conference play and rank in the top 10 for opponent hitting percentage (.157) and digs per set (15.0). Harper Murray leads with 294 kills, and Bergen Reilly has tallied 998 assists. The Badgers have won 10 of their last 11 matches and lead the Big Ten in team hitting percentage (.308) and blocks per set (3.1). Sarah Franklin has 393 kills, while CC Crawford leads the defense with 99 blocks. Who : Nebraska vs. Wisconsin Women’s College Volleyball When : Saturday, November 23 at 8 p.m. ET Where : Devaney Center in Linclon, NE Stream : FuboTV (free trial); Sling ; DirecTV Stream What is FuboTV? FuboTV is an internet television service that offers more than 200 channels across sports and entertainment including Paramount+ with SHOWTIME . From the UEFA Champions League to the WNBA to international tournaments, there are plenty of options available on FuboTV, which offers a free trial, and $20 off the first month for new customers. What is DirecTV Stream? DirecTV Stream offers practically everything DirecTV provides, except for a remote and a streaming device to connect to your television. Sign up now and get three free months of premium channels including MAX , Paramount+ with SHOWTIME and Starz. What is SlingTV? SlingTV offers a variety of live programming ranging from news and sports and starting as low as $20 a month for your first month. Subscribers also get a month of DVR Plus free if they sign up now. Choose from a variety of sports packages without long-term contracts and with easy cancelation. More College Football The Associated Press contributed to this article.Stock market today: Rising tech stocks pull Wall Street to another record